Antisoma shares plunge after latest cancer drug setback
Tuesday 01 February 2011
Antisoma suffered a blow last night after it revealed that a key acute leukaemia drug had failed in a final-stage clinical trial.
The biotech firm said it had also halted the development of another cancer treatment after early data from an ongoing penultimate-stage trial showed that the result was likely to be inconclusive.
The news triggered a sharp sell-off in Antisoma's shares, which closed at 2.2p, down more than 64 per cent. The decline leaves the firm valued at around £14m.
Glyn Edwards, Antisoma's chief executive, said the company had not seen a benefit with the AS1413 leukaemia treatment. "This is hugely disappointing for patients, investigators, investors and employees" he said. "We will now become smaller and focus on maximising the value of our other programmes."
Paul Cuddon at the Peel Hunt brokerage said the developments meant that "other than a £23m cash balance, which is continuing to decline, there are few assets left to value in the Antisoma pipeline".
He warned: "Other than 3.5p of cash, which we anticipate will fall to 2p, little value remains in Antisoma, and sadly we fail to see an ongoing future."
Samir Devani at Nomura Code Securities said the failure of the AS1413 final-stage trial was "not a huge surprise" as he had only assumed a 30 per cent chance of success.
The setback did, however, have a "major impact" on Antisoma's valuation, he added.
"We expect the company to go into cash-conserving mode and anticipate a significant restructuring in the near-term," he explained.
The latest setback comes less than a year after Antisoma's key lung cancer drug, ASA404, failed in March.
- 1 Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
- 2 Prince held a Facebook Q&A and this is the only question he answered
- 3 Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
- 4 Now we know whose fault it is if you end up being murdered in Thailand
- 5 35,000 walrus gather ashore on north-west Alaska beach 'for a rest'
Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
Car tax disc changes: Five facts you never knew about your (almost obsolete) tax disc
The Aral Sea: Nasa pictures show how what was once the fourth largest lake in the world has become almost completely dry
Brad Pitt, on the moment he completely lost his temper with Clint Eastwood's son
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
The Osborne Ultimatum: Chancellor’s benefits freeze bombshell will affect ten million households
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Should gay sex be illegal? 16% of Britons think so
Mark Reckless becomes second Tory MP to defect to Ukip in a month
Benefits 'smart cards' plan revealed by Iain Duncan Smith to stop claimants spending welfare money on alcohol
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...